NEW YORK--(BUSINESS WIRE)--Kroll Bond Rating Agency (KBRA) is pleased to announce the assignment of preliminary ratings to seven classes of VMC 2019-FL3, a $627.5 million commercial real estate ...
Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL). This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results